Cite
Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
MLA
Broadwell, Aaron, et al. “Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.” The Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 2, Jan. 2021, pp. 397–409. EBSCOhost, https://doi.org/10.1210/clinem/dgaa851.
APA
Broadwell, A., Chines, A., Ebeling, P. R., Franek, E., Huang, S., Smith, S., Kendler, D., Messina, O., & Miller, P. D. (2021). Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. The Journal of Clinical Endocrinology and Metabolism, 106(2), 397–409. https://doi.org/10.1210/clinem/dgaa851
Chicago
Broadwell, Aaron, Arkadi Chines, Peter R Ebeling, Edward Franek, Shuang Huang, Shawna Smith, David Kendler, Osvaldo Messina, and Paul D Miller. 2021. “Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.” The Journal of Clinical Endocrinology and Metabolism 106 (2): 397–409. doi:10.1210/clinem/dgaa851.